Anúncio
Anúncio
RARE
Ultragenyx Pharmaceutical Inc.
23.61
USDPatrocinado
+0.61
+2.63%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
23.55
-0.06
-0.24%
Relatórios de Lucros RARE
Rácio de surpresa positiva
RARE separação 20 de 40 últimas estimativas.
50%
Próximo Relatório
Data do Próximo Relatório
11 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$191.52M
/-$1.19
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+19.75%
/-34.25%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+16.16%
/-14.39%
Ultragenyx Pharmaceutical Inc. earnings per share and revenue
On 04 de nov. de 2025, RARE reported earnings of -1.81 USD per share (EPS) for Q3 25, missing the estimate of -1.25 USD, resulting in a -43.74% surprise. Revenue reached 159.93 milhão, compared to an expected 170.04 milhão, with a -5.95% difference. The market reacted with a -1.82% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 22 analistas forecast an EPS of -1.19 USD, with revenue projected to reach 191.52 milhão USD, implying an diminuir of -34.25% EPS, and aumentar of 19.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.81, missing estimates by -43.74%, and revenue of $159.93M, -5.95% below expectations.
How did the market react to Ultragenyx Pharmaceutical Inc.'s Q3 2025 earnings?
The stock price moved down -1.82%, changed from $32.46 before the earnings release to $31.87 the day after.
When is Ultragenyx Pharmaceutical Inc. expected to report next?
The next earning report is scheduled for 11 de fev. de 2026.
What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?
Based on 22
analistas, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.19 and revenue of $191.52M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio